Skip to main content

Ivosidenib leads to complete responses in 32% of IDH1-mutated relapsed/refractory AML

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Ivosidenib leads to complete responses in 32% of IDH1-mutated relapsed/refractory AML

User login

Username

Password

Reset your password

Type	Lead	score